353 related articles for article (PubMed ID: 32564899)
1. Causes and Consequences of Snake Venom Variation.
Casewell NR; Jackson TNW; Laustsen AH; Sunagar K
Trends Pharmacol Sci; 2020 Aug; 41(8):570-581. PubMed ID: 32564899
[TBL] [Abstract][Full Text] [Related]
2. Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
Alomran N; Alsolaiss J; Albulescu LO; Crittenden E; Harrison RA; Ainsworth S; Casewell NR
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009659. PubMed ID: 34407084
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms.
Alomran N; Blundell P; Alsolaiss J; Crittenden E; Ainsworth S; Dawson CA; Edge RJ; Hall SR; Harrison RA; Wilkinson MC; Menzies SK; Casewell NR
Toxins (Basel); 2022 Jun; 14(7):. PubMed ID: 35878181
[TBL] [Abstract][Full Text] [Related]
4. Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise.
Slagboom J; Kool J; Harrison RA; Casewell NR
Br J Haematol; 2017 Jun; 177(6):947-959. PubMed ID: 28233897
[TBL] [Abstract][Full Text] [Related]
5. A Review of the Proteomic Profiling of African Viperidae and Elapidae Snake Venoms and Their Antivenom Neutralisation.
Offor BC; Muller B; Piater LA
Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355973
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Utility of ssDNA Aptamers Directed against Snake Venom Toxins as New Therapeutics for Snakebite Envenoming.
Alomran N; Chinnappan R; Alsolaiss J; Casewell NR; Zourob M
Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878207
[TBL] [Abstract][Full Text] [Related]
7. The concept of Big Four: Road map from snakebite epidemiology to antivenom efficacy.
Gopal G; Muralidar S; Prakash D; Kamalakkannan A; Indhuprakash ST; Thirumalai D; Ambi SV
Int J Biol Macromol; 2023 Jul; 242(Pt 1):124771. PubMed ID: 37169043
[TBL] [Abstract][Full Text] [Related]
8. Defining the pathogenic threat of envenoming by South African shield-nosed and coral snakes (genus Aspidelaps), and revealing the likely efficacy of available antivenom.
Whiteley G; Casewell NR; Pla D; Quesada-Bernat S; Logan RAE; Bolton FMS; Wagstaff SC; Gutiérrez JM; Calvete JJ; Harrison RA
J Proteomics; 2019 Apr; 198():186-198. PubMed ID: 30290233
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms.
Zdenek CN; den Brouw BO; Dashevsky D; Gloria A; Youngman NJ; Watson E; Green P; Hay C; Dunstan N; Allen L; Fry BG
Toxicol Lett; 2019 Nov; 316():171-182. PubMed ID: 31442586
[TBL] [Abstract][Full Text] [Related]
10. Medically important differences in snake venom composition are dictated by distinct postgenomic mechanisms.
Casewell NR; Wagstaff SC; Wüster W; Cook DA; Bolton FM; King SI; Pla D; Sanz L; Calvete JJ; Harrison RA
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9205-10. PubMed ID: 24927555
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in diagnostic tools and bioanalytical methods for analysis of snake venom: A critical review.
Puzari U; Mukherjee AK
Anal Chim Acta; 2020 Nov; 1137():208-224. PubMed ID: 33153604
[TBL] [Abstract][Full Text] [Related]
12. Antivenom Neutralization of Coagulopathic Snake Venom Toxins Assessed by Bioactivity Profiling Using Nanofractionation Analytics.
Xie C; Slagboom J; Albulescu LO; Bruyneel B; Still KBM; Vonk FJ; Somsen GW; Casewell NR; Kool J
Toxins (Basel); 2020 Jan; 12(1):. PubMed ID: 31963329
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte haemotoxicity profiling of snake venom toxins after nanofractionation.
Xie C; Bittenbinder MA; Slagboom J; Arrahman A; Bruijns S; Somsen GW; Vonk FJ; Casewell NR; García-Vallejo JJ; Kool J
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1176():122586. PubMed ID: 33839052
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Drug Discovery for Neglected Tropical Snakebite.
Clare RH; Hall SR; Patel RN; Casewell NR
Trends Pharmacol Sci; 2021 May; 42(5):340-353. PubMed ID: 33773806
[TBL] [Abstract][Full Text] [Related]
15. Assessment of snakebite management practices at Meserani Juu in Monduli District, Northern Tanzania.
Iddi S; Justin J; Hamasaki K; Konje ET; Kongola GW
PLoS One; 2022; 17(12):e0278940. PubMed ID: 36548357
[TBL] [Abstract][Full Text] [Related]
16. Perspective on the Therapeutics of Anti-Snake Venom.
Gómez-Betancur I; Gogineni V; Salazar-Ospina A; León F
Molecules; 2019 Sep; 24(18):. PubMed ID: 31505752
[TBL] [Abstract][Full Text] [Related]
17. Snake venomics and antivenomics: Proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming.
Gutiérrez JM; Lomonte B; León G; Alape-Girón A; Flores-Díaz M; Sanz L; Angulo Y; Calvete JJ
J Proteomics; 2009 Mar; 72(2):165-82. PubMed ID: 19344652
[TBL] [Abstract][Full Text] [Related]
18. Commercial Antivenoms Exert Broad Paraspecific Immunological Binding and In Vitro Inhibition of Medically Important
Alsolaiss J; Alomran N; Hawkins L; Casewell NR
Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668821
[TBL] [Abstract][Full Text] [Related]
19. Toxin-centric development approach for next-generation antivenoms.
Laustsen AH
Toxicon; 2018 Aug; 150():195-197. PubMed ID: 29857088
[No Abstract] [Full Text] [Related]
20. Pharmacological re-assessment of traditional medicinal plants-derived inhibitors as antidotes against snakebite envenoming: A critical review.
Puzari U; Fernandes PA; Mukherjee AK
J Ethnopharmacol; 2022 Jun; 292():115208. PubMed ID: 35314419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
